Translational Profiling for Oncogenic mTOR Signaling Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene expression studies fail to effectively characterize translational control of mRNAs in oncogenic mTOR signaling, which is crucial for understanding cancer development and identifying therapeutic targets.
Innovation Solution
A method involving contacting a biological sample with an agent, determining translational profiles for genes with 5' terminal oligopyrimidine tracts or pyrimidine-rich elements, and comparing these profiles to control samples to identify modulators of oncogenic signaling pathways, specifically using ribosomal profiling, polysome microarray, or mass spectrometry analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If gene expression studies are used to examine mRNA in cell populations, then information about gene expression changes can be obtained, but the translational control of mRNAs cannot be effectively characterized
Solution Approach 1:
The patent introduces ribosome profiling as an intermediary technique that bridges the gap between mRNA level measurement and protein synthesis measurement. By sequencing ribosome-protected mRNA fragments, the method provides direct measurement of translational activity, serving as a mediator between transcriptional and translational control analysis
Solution Approach 2:
The patent replaces traditional mechanical/biochemical methods of measuring protein synthesis (such as radiolabeled amino acid incorporation) with a sequencing-based approach. This substitution enables genome-wide, high-throughput measurement of translational levels with greater precision and without the limitations of traditional methods
2Loss of information
If genome-scale predictions of synthesis rates are used, then information about protein abundance control can be demonstrated, but direct measurement of translational levels in specific pathways remains unavailable
Solution Approach 1:
The ribosome profiling method described in the patent is universally applicable to any gene or pathway of interest. The same sequencing-based platform can measure translational levels across the entire genome or focus on specific oncogenic pathways, providing multi-functional capability that eliminates the need for pathway-specific assay development
Solution Approach 2:
The patent changes the fundamental parameter measured from mRNA abundance to ribosome occupancy/translation efficiency. By sequencing ribosome-protected fragments and comparing them to total mRNA sequences, the method directly quantifies translational parameters rather than inferring them from mRNA levels, providing direct measurement capability
3Loss of information
If traditional gene expression analysis is used, then common pathways of genomic response can be identified, but treatment-specific translational control mechanisms remain undetected
Solution Approach 1:
The patent performs preliminary ribosome profiling under different treatment conditions to establish baseline translational profiles. By pre-characterizing translational control mechanisms across multiple conditions, the method enables easy comparison and identification of treatment-specific effects without requiring complex follow-up experiments
Solution Approach 2:
The patent creates a comprehensive copy of the translational landscape by sequencing ribosome-protected fragments across the genome. This digital copy of translational activity can be stored, compared, and analyzed using bioinformatic tools, making the complex data easily accessible and comparable across different experimental conditions
Data Source
Figure 1a~1g
Figure 2a~2e
Figure 3a~3g
AI summary
The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.